These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38816091)

  • 21. Drug-induced interstitial lung diseases.
    Gockerman JP
    Clin Chest Med; 1982 Sep; 3(3):521-36. PubMed ID: 6751669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulmonary drug toxicity: radiologic and pathologic manifestations.
    Rossi SE; Erasmus JJ; McAdams HP; Sporn TA; Goodman PC
    Radiographics; 2000; 20(5):1245-59. PubMed ID: 10992015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulmonary disease as a complication of chlorozotocin chemotherapy.
    Ahlgren JD; Smith FP; Kerwin DM; Sikic BI; Weiner JH; Schein PS
    Cancer Treat Rep; 1981; 65(3-4):223-9. PubMed ID: 6453644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
    Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
    Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pulmonary complications of cancer therapy.
    Wesselius LJ
    Compr Ther; 1992 Mar; 18(3):17-20. PubMed ID: 1572146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review: diagnosis of chemotherapy lung.
    Sostman HD; Putman CE; Gamsu G
    AJR Am J Roentgenol; 1981 Jan; 136(1):33-40. PubMed ID: 6161531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib.
    Gemma A; Kusumoto M; Kurihara Y; Masuda N; Banno S; Endo Y; Houzawa H; Ueno N; Ohki E; Yoshimura A
    J Thorac Oncol; 2019 Apr; 14(4):672-682. PubMed ID: 30521972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: A systematic review and meta-analysis of randomized clinical trials.
    Nozawa K; Takatsuka D; Endo Y; Horisawa N; Ozaki Y; Kataoka A; Kotani H; Yoshimura A; Hattori M; Sawaki M; Iwata H
    Crit Rev Oncol Hematol; 2022 Jun; 174():103703. PubMed ID: 35533814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Specific adverse events caused by monoclonal antibodies, focusing on the prophylaxis and management].
    Akiyama S
    Nihon Rinsho; 2012 Dec; 70(12):2199-204. PubMed ID: 23259397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study.
    Nakamura K; Kato M; Shukuya T; Mori K; Sekimoto Y; Ihara H; Kanemaru R; Ko R; Shibayama R; Tajima K; Koyama R; Shimada N; Nagashima O; Takahashi F; Sasaki S; Takahashi K
    BMC Cancer; 2017 May; 17(1):302. PubMed ID: 28464801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of pulmonary toxicity associated with immune checkpoint inhibitors.
    Delaunay M; Prévot G; Collot S; Guilleminault L; Didier A; Mazières J
    Eur Respir Rev; 2019 Dec; 28(154):. PubMed ID: 31694838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
    Ando M; Okamoto I; Yamamoto N; Takeda K; Tamura K; Seto T; Ariyoshi Y; Fukuoka M
    J Clin Oncol; 2006 Jun; 24(16):2549-56. PubMed ID: 16735708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pulmonary complications of novel antineoplastic agents for solid tumors.
    Vahid B; Marik PE
    Chest; 2008 Feb; 133(2):528-38. PubMed ID: 18252919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients.
    Beom SH; Kim DW; Sim SH; Keam B; Park JH; Lee JO; Kim TM; Lee SH; Heo DS
    Cancer Res Treat; 2016 Jan; 48(1):88-97. PubMed ID: 25761482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Respiratory complications of anticancer chemotherapy].
    Leclerc P; Robillard M
    Rev Pneumol Clin; 1986; 42(3):142-9. PubMed ID: 3534991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world.
    Kaku S; Horinouchi H; Watanabe H; Yonemori K; Okusaka T; Boku N; Yamazaki N; Kawai A; Ohe Y; Kusumoto M
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1737-1746. PubMed ID: 35129672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms.
    Fessas P; Possamai LA; Clark J; Daniels E; Gudd C; Mullish BH; Alexander JL; Pinato DJ
    Immunology; 2020 Feb; 159(2):167-177. PubMed ID: 31646612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pulmonary dysfunction in pediatric oncology patients.
    Meyer S; Reinhard H; Gottschling S; Nunold H; Graf N
    Pediatr Hematol Oncol; 2004 Mar; 21(2):175-95. PubMed ID: 15160517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.
    Hadjinicolaou AV; Nisar MK; Bhagat S; Parfrey H; Chilvers ER; Ostör AJ
    Rheumatology (Oxford); 2011 Dec; 50(12):2297-305. PubMed ID: 22019799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports.
    Yoshii N; Suzuki T; Nagashima M; Kon A; Kakihata K; Gemma A
    Anticancer Drugs; 2011 Jul; 22(6):563-8. PubMed ID: 21562406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.